Gene therapies, along with genome editors based on the CRISPR-Cas systems, have become a new approach for treating diseases caused by pathogenic variants in various organs, including the liver, muscles, lungs, and the central nervous system. However, delivery to the kidney remains challenging. In this project, our goal is to establish a kidney delivery platform with the potential to correct monogenic kidney diseases using base editors. Due to the kidney's complex anatomy, we explore microsurgical methods for targeted renal delivery of adeno-associated viruses (AAVs). Local renal pelvis, artery, and vein injections, as well as systemic tail vein injection routes, were tested in Ai14 reporter mice to target different kidney cell types using the serotypes AAV8 and AAV9. In this mouse model, AAV-mediated delivery of a Cre recombinase leads to the excision of a loxP-flanked STOP cassette and consequently induces tdTomato expression. Flow cytometry (FC) results showed approximately 90% transduction in the liver, independent of the injection route, compared to up to 6% in the kidney with renal artery injections. Immunofluorescence revealed a delivery route-dependent distribution of tdTomato-expressing cells. The reporter system allows for the quantitative analysis of renal in-vivo delivery and the systematic optimization of transduction efficiency. Ongoing experiments include the use of cell-type specific promoters and testing of non-viral delivery approaches to enhance efficiency and specificity.